ATE531732T1 - Bi-spezifische antikörper, die auf an reaktionen vom allergischen typ beteiligte zellen zielen, zusammensetzungen und anwendungen davon - Google Patents

Bi-spezifische antikörper, die auf an reaktionen vom allergischen typ beteiligte zellen zielen, zusammensetzungen und anwendungen davon

Info

Publication number
ATE531732T1
ATE531732T1 AT05718931T AT05718931T ATE531732T1 AT E531732 T1 ATE531732 T1 AT E531732T1 AT 05718931 T AT05718931 T AT 05718931T AT 05718931 T AT05718931 T AT 05718931T AT E531732 T1 ATE531732 T1 AT E531732T1
Authority
AT
Austria
Prior art keywords
specific
compositions
specific antibodies
type reactions
allergic
Prior art date
Application number
AT05718931T
Other languages
English (en)
Inventor
Francesca Levi-Schaffer
Ido Bachelet
Ariel Munitz
Lorenzo Moretta
Alessandro Moretta
Original Assignee
Yissum Res Dev Co
Dimes Dipartimento Do Medicina Sperimentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Dimes Dipartimento Do Medicina Sperimentale filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE531732T1 publication Critical patent/ATE531732T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
AT05718931T 2004-03-30 2005-03-30 Bi-spezifische antikörper, die auf an reaktionen vom allergischen typ beteiligte zellen zielen, zusammensetzungen und anwendungen davon ATE531732T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55737704P 2004-03-30 2004-03-30
PCT/IL2005/000358 WO2005095460A2 (en) 2004-03-30 2005-03-30 Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof

Publications (1)

Publication Number Publication Date
ATE531732T1 true ATE531732T1 (de) 2011-11-15

Family

ID=35064449

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05718931T ATE531732T1 (de) 2004-03-30 2005-03-30 Bi-spezifische antikörper, die auf an reaktionen vom allergischen typ beteiligte zellen zielen, zusammensetzungen und anwendungen davon

Country Status (6)

Country Link
US (1) US8133485B2 (de)
EP (1) EP1730194B1 (de)
JP (1) JP4939397B2 (de)
AT (1) ATE531732T1 (de)
ES (1) ES2375481T3 (de)
WO (1) WO2005095460A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
ITRM20050297A1 (it) * 2005-06-08 2006-12-09 Univ Siena Anticorpi diretti contro la proteina basica della mielina che riconoscono un epitopo del cd64 e uso di essi come immunodepressivi.
SG155912A1 (en) 2005-07-25 2009-10-29 Trubion Pharmaceuticals Inc B-cell reduction using cd37-specific and cd20-specific binding molecules
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
JP6149226B2 (ja) 2010-10-01 2017-06-21 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
JP2013079210A (ja) * 2011-10-04 2013-05-02 Nagoya City Univ 治療剤、遺伝子治療剤及び好酸球の浸潤抑制方法
DK2808028T3 (da) 2011-11-21 2019-10-07 Univ Tsukuba Aktivitetsmodulator, medicinsk middel omfattende samme, anvendelse af mus med cd300a-gen-mangel og anti-cd300a antistof
EP3381943B1 (de) 2012-07-25 2022-03-16 Celldex Therapeutics, Inc. Anti-kit-antikörper und verwendungen davon
EP2918289A4 (de) 2012-11-07 2016-06-15 Univ Tsukuba Medikament mit modulator der aktivität einer cd300a-exprimierender zelle im zusammenhang mit allergischen erkrankungen, cd300a-gen-knockout-maus und verwendung eines modulators der aktivität einer cd300a-exprimierender zelle
WO2014188423A1 (en) 2013-05-21 2014-11-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
WO2015058861A1 (en) * 2013-10-25 2015-04-30 Numab Ag Bispecific constructs and their use in the treatment of various diseases
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
CA2959775A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
EP3352760B1 (de) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3-bindende polypeptide
EP3176183A1 (de) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Zusammensetzungen und verfahren zur behandlung von krebs ohne resistenz gegen einen tyrosinkinasehemmer (tki)
EP3841201A1 (de) 2018-08-24 2021-06-30 Yeda Research and Development Co. Ltd Verfahren zur modulation der m2-makrophagenpolarisation und verwendung derselben in der therapie
US11730762B2 (en) 2018-08-30 2023-08-22 HCW Biologics, Inc. Methods for stimulating proliferation or differentiation of an immune cell with a multi-chain chimeric polypeptide
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
JPWO2020166714A1 (ja) * 2019-02-15 2021-12-16 国立大学法人愛媛大学 複合体化タンパク質、抗体複合体、医薬組成物、および核酸
CN114269903B (zh) 2019-06-21 2025-11-25 免疫生物公司 多链嵌合多肽和其用途
AU2021220196A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of activating regulatory T cells
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
JP2023513573A (ja) 2020-02-11 2023-03-31 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢性および炎症性疾患を治療する方法
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗cd26タンパク質及びそれらの使用法
IL298608A (en) 2020-06-01 2023-01-01 Hcw Biologics Inc Methods for treating disorders related to aging
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4130028A1 (de) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Manipulierter tcr-komplex und verfahren zur verwendung davon
JP2024536647A (ja) 2021-08-03 2024-10-07 ジェニシティー リミテッド 操作されたtcr複合体及びそれを使用する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064662A1 (en) * 2001-03-16 2003-08-07 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy of allergies
ES2321701T3 (es) * 2001-10-12 2009-06-10 Schering Corporation Uso de anticuerpos biespecificos que se unen al receptor de activacion fcepsilonri y al receptor de inhibicion ox2ra (cd200ra) para regular respuestas inmunes.

Also Published As

Publication number Publication date
WO2005095460A3 (en) 2006-03-30
JP2007537157A (ja) 2007-12-20
US8133485B2 (en) 2012-03-13
EP1730194B1 (de) 2011-11-02
WO2005095460A2 (en) 2005-10-13
EP1730194A2 (de) 2006-12-13
US20080219980A1 (en) 2008-09-11
ES2375481T3 (es) 2012-03-01
JP4939397B2 (ja) 2012-05-23

Similar Documents

Publication Publication Date Title
ATE531732T1 (de) Bi-spezifische antikörper, die auf an reaktionen vom allergischen typ beteiligte zellen zielen, zusammensetzungen und anwendungen davon
Pilch et al. Targeting human telomeric G-quadruplex DNA with oxazole-containing macrocyclic compounds
Kumar et al. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications
GB201010589D0 (en) Method and device
WO2007120842A3 (en) Methods and compositions for targeting c-rel
ATE531733T1 (de) Kir-bindende wirkstoffe und verfahren zu ihrer verwendung
Luo et al. Synthesis, biological evaluation, 3D-QSAR studies of novel aryl-2H-pyrazole derivatives as telomerase inhibitors
WO2006051405A3 (en) Methods and means related to cancer stem cells
EA201000343A1 (ru) ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
WO2007067812A3 (en) Protein kinase modulation by hops and acacia products
WO2010100056A3 (en) Antibodies against a proliferating inducing ligand (april)
WO2006091837A3 (en) Small molecule inhibitors of stat3 and the uses thereof
WO2008104380A3 (en) Multiplex detection of tumour cells using a panel of agents binding to extracellular markers
BR112014006390A2 (pt) anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
ATE493439T1 (de) Monoklonale ykl-40-antikörper
WO2010120518A3 (en) Sperm cell separation methods and compositions containing sperm cell targeting ligands for use therein
MX2009013064A (es) Composiciones y metodos de uso de la interferencia de arn para el control de nematodos.
CR11079A (es) Anticuerpos contra il-25
WO2010126590A8 (en) Ptp1b inhibitors
DE602008002901D1 (de) 1-benzensulfonyl-1h-indol-derivate als hemmer der ccr9-aktivität
MY147438A (en) Biological materials and uses thereof
Tanzer A proteomic perspective on TNF-mediated signalling and cell death
Xiao et al. Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors
WO2007123636A9 (en) Compositions and methods comprising the use of cell surface displayed homing endonucleases